Business Context and Reporting Period
This Form 8-K was filed by Galectin Therapeutics Inc. on September 13, 2021. The report serves as a current disclosure pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The primary purpose of this filing is to disclose a corporate overview presentation posted to the company's website on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a presentation and does not contain audited financial statements or a summary of financial performance.
Material Changes
No material changes to financial position or operations are reported within the text of this filing. The document solely references the release of a corporate overview presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure (Item 7.01) regarding the attached presentation. The text explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Consequently, specific guidance, management commentary, risks, or contingencies are not detailed in the body of this report but are contained within the referenced Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Overview Presentation, September 2021) for detailed business updates, pipeline status, and financial outlook.
- Verify the company's current cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K does not provide updated financial figures.
- Confirm the trading status of the Common Stock (Symbol: GALT) on The Nasdaq Stock Market.
- Note that the information in this specific 8-K is not incorporated by reference into other filings unless expressly stated.